JP2021167324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021167324A5 JP2021167324A5 JP2021103895A JP2021103895A JP2021167324A5 JP 2021167324 A5 JP2021167324 A5 JP 2021167324A5 JP 2021103895 A JP2021103895 A JP 2021103895A JP 2021103895 A JP2021103895 A JP 2021103895A JP 2021167324 A5 JP2021167324 A5 JP 2021167324A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- molecule
- composition according
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 238000011282 treatment Methods 0.000 claims 15
- 230000004927 fusion Effects 0.000 claims 7
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 238000009169 immunotherapy Methods 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000002689 Toll-like receptor Human genes 0.000 claims 2
- 108020000411 Toll-like receptor Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100039328 Endoplasmin Human genes 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 108010022937 endoplasmin Proteins 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 108091008020 response regulators Proteins 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175024P | 2015-06-12 | 2015-06-12 | |
| US201562175044P | 2015-06-12 | 2015-06-12 | |
| US62/175,044 | 2015-06-12 | ||
| US62/175,024 | 2015-06-12 | ||
| US201562257852P | 2015-11-20 | 2015-11-20 | |
| US62/257,852 | 2015-11-20 | ||
| US201662321724P | 2016-04-12 | 2016-04-12 | |
| US62/321,724 | 2016-04-12 | ||
| JP2017563600A JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563600A Division JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021167324A JP2021167324A (ja) | 2021-10-21 |
| JP2021167324A5 true JP2021167324A5 (enExample) | 2021-12-23 |
Family
ID=57504236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563600A Pending JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
| JP2021103895A Pending JP2021167324A (ja) | 2015-06-12 | 2021-06-23 | がん治療のための集中インターフェロン免疫療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563600A Pending JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180312561A1 (enExample) |
| EP (1) | EP3307301A4 (enExample) |
| JP (2) | JP2018516950A (enExample) |
| AU (2) | AU2016274897B2 (enExample) |
| CA (1) | CA2988619A1 (enExample) |
| WO (1) | WO2016201251A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3577133A1 (en) * | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| WO2018144999A1 (en) * | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CN109810995B (zh) * | 2017-12-06 | 2020-10-02 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
| CN110194800B (zh) * | 2018-02-26 | 2022-11-18 | 张灏 | 一种融合蛋白、细胞外泌体和肿瘤疫苗及其应用 |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| AU2020398327A1 (en) | 2019-12-03 | 2022-07-14 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040001789A1 (en) * | 1999-10-08 | 2004-01-01 | Young David S. F. | Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof |
| KR101661770B1 (ko) * | 2007-09-21 | 2016-10-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함 |
| US9272029B2 (en) * | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| ES2611479T3 (es) * | 2010-06-16 | 2017-05-09 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Anticuerpos contra endoplasmina y su uso |
| WO2012170072A1 (en) * | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| CN104203982B (zh) * | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| PL2822575T3 (pl) * | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| WO2014163684A1 (en) * | 2013-04-03 | 2014-10-09 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
-
2016
- 2016-06-10 WO PCT/US2016/036925 patent/WO2016201251A1/en not_active Ceased
- 2016-06-10 EP EP16808391.3A patent/EP3307301A4/en not_active Withdrawn
- 2016-06-10 CA CA2988619A patent/CA2988619A1/en not_active Abandoned
- 2016-06-10 US US15/735,583 patent/US20180312561A1/en not_active Abandoned
- 2016-06-10 JP JP2017563600A patent/JP2018516950A/ja active Pending
- 2016-06-10 AU AU2016274897A patent/AU2016274897B2/en not_active Ceased
-
2021
- 2021-05-13 AU AU2021203042A patent/AU2021203042A1/en not_active Abandoned
- 2021-06-23 JP JP2021103895A patent/JP2021167324A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021167324A5 (enExample) | ||
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| CN107428832B (zh) | 抗pd-l1抗体 | |
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| JP2020515247A5 (enExample) | ||
| JP2019511212A (ja) | ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体 | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| US20180044428A1 (en) | Compositions and methods for enhancing the efficacy of cancer therapy | |
| JP2018516950A5 (enExample) | ||
| JP7606706B2 (ja) | ヒトネクチン－２に特異的な抗体 | |
| JP2016531090A (ja) | ヒト抗ｉｆｎ−アルファ抗体 | |
| WO2019206095A1 (zh) | 针对tim-3的抗体及其用途 | |
| WO2023166210A1 (en) | Anti pd-l2 antibody | |
| EP4263584A1 (en) | Combination therapy for the treatment of cancer | |
| US20230140694A1 (en) | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies | |
| TW202402799A (zh) | Ｔ細胞接合劑相關之不良反應之預防或減輕 | |
| EP3893888A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 | |
| US20220348653A1 (en) | Quantitative Spatial Profiling for LAG-3 Antagonist Therapy | |
| JP2022513246A (ja) | 抗ｃｅａｃａｍ６及びｔｉｍ３抗体の医薬組み合わせ | |
| JP2022513036A (ja) | がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ | |
| WO2023146394A1 (en) | Combination therapy for the treatment of cancer | |
| TW202400662A (zh) | 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途 | |
| JP7684656B2 (ja) | 免疫抑制剤 | |
| US20200148758A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof |